The US Food and Drug Administration (FDA) has approved Abbott’s new TactiCath Contact Force Ablation Catheter, Sensor Enabled, for the treatment of atrial fibrillation (AFib).

TactiCath has been developed to provide precise images of the heart along with real-time electrical activity information. Its design is said to enable superior reach and manoeuvrability during cardiac ablation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The device is part of Abbott cardiac ablation portfolio based on the company’s EnSite Precision cardiac mapping system to deliver accurate heart images while performing ablation procedures.

“TactiCath has been developed to provide precise images of the heart along with real-time electrical activity information. Its design is said to enable superior reach and manoeuvrability during cardiac ablation.”

TactiCath’s approval follows a recent FDA nod for Abbott’s Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA) in premature babies and newborns.

Abbott Electrophysiology business medical director Srijoy Mahapatra said: “TactiCath SE directly supports our goal of supporting fast, effective and safe cardiac ablation procedures.

“As more physicians turn to cardiac ablation to treat AFib, Abbott’s goal is to equip them with the most advanced ablation catheters combined with the most advanced cardiac mapping on the market.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ablation catheters are commonly used to treat AFib by scarring tissue in the heart that generates abnormal electrical signals and disrupts a patient’s natural heartbeat.

To date, Abbott cardiac ablation technology has been used for the treatment of patients in more than 84 countries globally.

Physicians are currently evaluating the use of new tools such as ‘contact force’ technology to help them apply appropriate pressure during ablation procedures.

Abbott has also invested in technology to enhance the accuracy of cardiac mapping in order to support the procedures.

The company launched new clinical trials to gather clinical evidence associated with cardiac ablation, as well as introduced the Advisor HD Grid Mapping Catheter, Sensor Enabled, and the FlexAbility Ablation Catheter, Sensor Enabled.